OUTSET MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.14 USD | +4.67% |
|
+30.83% | -41.96% |
| 04-17 | Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S | CI |
| 04-08 | BTIG Initiates Outset Medical at Buy Rating With $6 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company shows low valuation levels, with an enterprise value at 0.52 times its sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -41.96% | 162M | C- | ||
| +7.84% | 218B | B | ||
| +7.35% | 184B | B- | ||
| +13.04% | 135B | B- | ||
| -1.33% | 62.38B | A- | ||
| +11.80% | 51.37B | B+ | ||
| +4.81% | 50.9B | B+ | ||
| +0.30% | 40.87B | A | ||
| +2.78% | 36.28B | - | ||
| +26.14% | 31.88B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- OM Stock
- Ratings Outset Medical, Inc.